*Participants were a convenience sample recruited at the University of Alabama at Birmingham (Birmingham, AL, USA) during March–May 2020. Values are no. (%) unless otherwise indicated. C_t, cycle threshold; DFOS, days following onset of symptoms; IQR, interquartile range; RBD, receptor binding domain; RT-PCR, reverse transcription PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; T1, time of first serologic test. †Calculated using a likelihood ratio test for a logistic regression predicting seropositivity for the category indicated after Bonferroni correction for multiple comparisons, except for RT-PCR and serologic DFOS, for which p-values were calculated using a Welch’s 2-sample t-test. ‡C_t values were only available for a subset of seropositive (n = 34) and seronegative (n = 25) persons Appendix Table 1. §Symptom severity was self-reported, with 0 indicating no symptoms, 1 indicating mild symptoms with little impact on daily activities, 2 indicating moderate symptoms with noticeable impact on daily activities, and 3 indicating severe symptoms with a substantial reduction in quality of life (Appendix Table 1). ¶Above assay detection limits (Appendix Table 2 details midpoint and endpoint titers). #ELISA detection of IgG and IgA binding antibodies to a prefusion stabilized Wuhan-Hu-1 spike protein. **ELISA detection of IgM and IgG binding antibodies to RBD of the Wuhan-Hu-1 spike protein. ††Detection of IgG binding antibodies to the nucleocapsid protein by the Abbott Architect assay.